Iris reconstruction lens benefits aniridic patients
November 1st 2003Indianapolis-The Model 311 Iris Reconstruction Lens (Ophtec) appears safe and has significant benefit for reducing visual disturbances in patients with partial or complete aniridia, according to the first reported results from the FDA phase I trial evaluating that implant.
Mindset change brings eye doctors around to dispensing
October 15th 2003In the past, ophthalmologists have had the luxury of viewing themselves as specialized surgical and medical care providers and have not been driven to include a retail profit center, such as an optical dispensary, in their practice.
Large-spot-size TTT effective for CNV associated with AMD
October 15th 2003Two large clinical studies have confirmed that large-spot-size transpupillary thermotherapy (TTT) is efficacious for the treatment of occult choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
Endophotocoagulation easier with new laser probe
October 15th 2003Salisbury, MD-The BriteLight Illuminating EndoProbe, the newest addition to IRIDEX Corp.'s IRIS Medical delivery devices, is a high-quality, endolaser probe that delivers both high-intensity white light and laser light through a single handpiece.
Prototype offers OCT, SLO images of vitreoretinal pathologies
October 15th 2003New York-A new clinical device that simultaneously displays optical coherence tomography (OCT) and scanning laser ophthal- moscopy (SLO) images may be useful in analyzing vitreoretinal pathologies of the posterior segment.
Injectable lens possible solution to restore accommodation
October 15th 2003Groningen, The Netherlands-Early preclinical studies are yielding promise that an injected, artificial, capsule-filling lens may offer a possible solution for restoring accommodative ability lost in presbyopia or pseudophakia.
Improved outcomes possible with advanced technology
October 15th 2003London-The level of control a surgeon has today over customizing laser treatments for refractive surgery patients is very limited. Basically, surgeons are limited to control over the size of the fully corrected optical zone, and in some laser systems the size of the transition zone, according to Dan Rein-stein, MD, MA (Cantab), FRSC, DABO.
Pseudophakic IOL may suit cataract, refractive lens exchange
October 15th 2003San Francisco-Clinical trials have begun evaluating the Light-Adjustable Lens (LAL, Calhoun Vision), a unique silicone-based, pseudophakic IOL that would allow for non-invasive, postoperative correction of refractive and wavefront errors, said Daniel M. Schwartz, MD.
IOL implantation system yields ultra-small-incision surgery
October 15th 2003Nuremberg, Germany-The Acri.Smart 48S IOL implanted with the Acri.Glide/Acri.Shooter system (Acri.Tec, Berlin, Germany) enables cataract surgery to be performed completely with the benefits of ultra-small-incision techniques, said Wolfram Wehner, MD.
Injector system designed for use with pupil expansion device
October 15th 2003Sydney, Australia-The introduction of the Perfect Pupil Injector (Becton, Dickinson and Co. [BD]) has made implantation with the Perfect Pupil expansion device (BD) a very surgeon-friendly procedure, according to E. John Milverton, MD.
New drug developed to treat Fabry's disease
October 15th 2003New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.
Approach cataract surgery with care in presence of PXF
October 15th 2003Cataract surgery in the presence of pseudoexfoliation (PXF) of the lens presents surgeons with unusual challenges. In addition to a higher incidence of glaucoma, these patients have loss of zonular integrity occasionally associated with lens subluxation and pupils that dilate poorly. Although the use of phacoemulsification in experienced hands has resulted in a low incidence of intraoperative and postoperative complications such as zonular dialysis, capsule tears, vitreous loss, and IOL decentration,1 special care should still be exercised when performing cataract surgery in these patients. Improvements in phacoemulsification technology, technique, and capsular supporting rings should ultimately enable these patients to undergo
Ocular inflammation approach raises glaucoma risk
October 15th 2003Birmingham, AL-Glaucoma can arise as a complication of uveitis or as a result of steroids used to treat the inflammatory disorder, said Christopher A. Girkin, MD, associate professor of ophthalmology and director of the glaucoma service, University of Alabama, Birmingham. He reviewed information on the epidemiology, mechanisms, and management of inflammatory and steroid-induced glaucoma.
Glaucoma experts translate messages from NEI clinical trials
October 15th 2003Chicago-In the late 1980s, ophthalmologists were challenged by Eddy and Billings to prove that IOP was an essential element in the management of primary open-angle glaucoma (POAG). Recent results from a number of National Eye Institute (NEI)-sponsored randomized controlled trials confirm that IOP reduction is effective in slowing both disease development and its progression. The results of those studies, however, have raised new issues in glaucoma management.
Diffractive, bifocal IOL an option for refractive lens exchange
October 15th 2003Frankfurt, Germany-Refractive lens exchange with diffractive, bifocal IOL implantation can offer a good option for improving distance vision and restoring near visual acuity in some presbyopic-age patients, said Thomas Kohnen, MD.
Eyeing contacts for the over-40 crowd
October 15th 2003Portland, OR-Now, more than ever, people with presbyopia are seeking to put aside their glasses to wear contact lenses. Aging baby boomers prefer to see and be seen without glasses. Career-oriented, they are involved in activities that require good vision not only at near and at distance, but also in the intermediate range.
Laser vision correction of presbyopia possible
October 15th 2003Halifax, Nova Scotia-In a small group of hyperopic patients, laser vision correction (LVC) with multifocal ablations seems to be an advantageous approach for improving both near and distance visual acuity, explained W. Bruce Jackson, MD, FRCSC, during the annual meeting of the Canadian Ophthalmologic Society here.
AAO makes case for OPT for Medicare patients
October 15th 2003Washington, DC-The Medicare Coverage Advisory Committee has voted overwhelmingly in favor of making ocular photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) available as a valid and important treatment for treating AMD in select patients with subfoveal choroidal neovascularization (CNV) with occult but no classic CNV.